Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.
This data necessitates careful consideration of donanemab's clinical meaningfulness in early symptomatic Alzheimer disease, particularly regarding its modest effect on functional decline.
💡 Clinical Impact
* Mechanistic Why: Donanemab targets and clears deposited amyloid plaques, a pathological hallmark of AD, demonstrating a direct biological intervention.
* Clinical/Systemic Benefit: While demonstrating